.

ISSN 2063-5346
For urgent queries please contact : +918130348310

ANIMAL MODELS FOR BREAST CANCER STUDIES AND THEIR APPLICATION IN DRUG DEVELOPMENT

Main Article Content

Singh Jyoti, Gautam Dev Nath Singh , Priyanka, Ranjan Rohit , Sourav Simant
» doi: 10.31838/ecb/2023.12.si4.143

Abstract

Preclinical models of breast cancers are indispensable in the drug discovery and development process for new cancer drugs, small molecules and biologics. They are however imperfect facsimiles of breast cancers given the genetic and epigenetic heterogeneity of the latter and the multiplicity of dysregulated survival and growth-regulatory pathways that characterize this spectrum of diseases. Although markers for early diagnosis and drugs that limit the spread of breast cancer to other organs have been developed, it is difficult to prevent the relapse of breast cancer. Additionally, evaluating the efficacy of novel therapeutic agents emerging from drug discovery programs in a variety of pre-clinical models can better mimic the heterogeneity of human cancers and also aid in establishing dose levels, dose regimens and drug combinations for use in clinical trials. Nonetheless, despite the sophistication and physiological relevance of these breast cancer models (e.g., genetically engineered tumor models and primary human tumografts), the ultimate proof of concept for efficacy and safety of novel oncology therapeutics lies in humans. The information for the present study was obtained from various internet sources like research articles and paper presentation documents and research book publications. Emerging data have suggested that animal models are a good system to investigate this communication. Therefore, studies with animal models have been developed as a reasonable method for a systemic approach to understand breast cancer metastasis. In this review, we summarize animal models of breast cancer and their applications to the study of human breast cancers, and discuss limitation of model system and advanced techniques to overcome it.

Article Details